Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials
Kathleen M Andersen, Jonathan TL Cheah, Lyn March, Susan J Bartlett, Dorcas Beaton, Clifton O Bingham, Peter M Brooks, Robin Christensen, Philip G Conaghan, Maria-Antonietta D'Agostino, Maarten de Wit, Amylou C Dueck, Susan M Goodman, Shawna Grosskleg, Catherine L Hill, Martin Howell, Sarah L Mackie, Bethan Richards, Beverly Shea, Jasvinder A Singh Show all
The Journal of Rheumatology | J RHEUMATOL PUBL CO | Published : 2019
OBJECTIVE: Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases. METHODS: Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings. RESULTS: Five themes pertaining to drug safety measurement emerged. CONCLUSION: Current approaches have failed to incl..View full abstract
Awarded by Oak Foundation
The Parker Institute, Bispebjerg and Frederiksberg Hospital (RC) is supported by a core grant from the Oak Foundation (OCAY-13-309). PGC is supported in part by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.